Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYN-001 in Healthy Adults and Atopic Dermatitis
NCT07746817Phase 1Recruiting
- Sponsor
- Bionyra Pharma
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BYN-001 in atopic dermatitis (AD) (6 arms), sponsored by Bionyra Pharma. Primary endpoint: Adverse Events at 48 weeks. Started Aug 2026; status: recruiting.
02
Drugs
BYN-001
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07746817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746817.